Short answer
aTYR PHARMA INC (ATYR) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers aTyr Pharma’s quarter ended September 30, 2026.
aTYR PHARMA INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers aTyr Pharma’s quarter ended September 30, 2026
- Financial results and management commentary available in Exhibit 99.1
- Quarterly disclosure provides investors an update on operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- FDA-aligned Phase 3 efzofitimod protocol, using FVC as primary endpoint, moves pulmonary sarcoidosis program toward pivotal testing
- Strategic partnerships or licensing now prioritized, creating execution and funding dependence on external financing or collaboration
- EFZO-CONNECT Phase 2 enrollment completed, with systemic sclerosis ILD results expected in Q2 2027
- Cash and investments $50.3M at September 30, 2026, supporting operations into late 2028 under current plans
- Q3 net loss $18.3M, R&D expense $10.4M, and G&A expense $8.3M; cash declined from $80.9M at December 31, 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other aTYR PHARMA INC 8-K filings
Get the next ATYR 8-K as it lands
Follow ATYR for push alerts, or ask the research agent what this filing means.